Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

1361009

USP

Levodopa

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

3,4-Dihydroxy-L-phenylalanine, 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
(HO)2C6H3CH2CH(NH2)CO2H
Numero CAS:
59-92-7
Peso molecolare:
197.19
Beilstein:
2215169
Numero MDL:
MFCD00002598
Codice UNSPSC:
41116107
ID PubChem:
329750042
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

levodopa

Produttore/marchio commerciale

USP

Punto di fusione

276-278 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
WTDRDQBEARUVNC-LURJTMIESA-N

Informazioni sul gene

human ... DRD3(1814)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Levodopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H315,H319,H335

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Carbidopa European Pharmacopoeia (EP) Reference Standard

C0460000

Carbidopa

L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride solid

Sigma-Aldrich

D1507

L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride

Carbidopa British Pharmacopoeia (BP) Reference Standard

BP060

Carbidopa

Benserazide hydrochloride European Pharmacopoeia (EP) Reference Standard

B0477000

Benserazide hydrochloride

vibrant-m

Y0001249

Entacapone

Benserazide hydrochloride British Pharmacopoeia (BP) Reference Standard

BP685

Benserazide hydrochloride

Benserazide hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B7283

Benserazide hydrochloride

Methyldopa United States Pharmacopeia (USP) Reference Standard

USP

1426002

Methyldopa

Damian M Herz et al.
Annals of neurology, 75(6), 829-836 (2014-06-04)
In Parkinson disease (PD), long-term treatment with the dopamine precursor levodopa gradually induces involuntary "dyskinesia" movements. The neural mechanisms underlying the emergence of levodopa-induced dyskinesias in vivo are still poorly understood. Here, we applied functional magnetic resonance imaging (fMRI) to
Pol Nadal-Jimenez et al.
Journal of bacteriology, 196(14), 2681-2690 (2014-05-13)
The iron binding siderophore pyoverdine constitutes a major adaptive factor contributing to both virulence and survival in fluorescent pseudomonads. For decades, pyoverdine production has allowed the identification and classification of fluorescent and nonfluorescent pseudomonads. Here, we demonstrate that PvdP, a
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
Lukas L Imbach et al.
Parkinsonism & related disorders, 20(11), 1283-1286 (2014-09-28)
Diagnosis and treatment of tremor are largely based on clinical assessment. Whereas in some patients tremor may respond to dopaminergic treatment, in general l-Dopa response to tremor varies considerably. The aim of this study was to predict l-Dopa response by
Vincent J J Odekerken et al.
Neurology, 84(13), 1355-1361 (2015-03-01)
To assess the neuropsychological outcome 12 months after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN) for advanced Parkinson disease. We randomly assigned patients to receive either GPi DBS or STN DBS.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.